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Abstract
Background: Osteoarthritis (OA) is the final result of progressive alterations to articular cartilage structure, composition
and cellularity, followed by an increase in the concentration of pro-inflammatory cytokines in joint synovial fluid. Even
though the effect of pulsed electromagnetic field (PEMF) stimulation in counteracting OA progression and inflammation
is of increasing interest, because of its anabolic and anti-inflammatory properties, the present study aimed to improve
the knowledge on cartilage extracellular matrix (ECM) and chondrocyte changes related to the exposure of PEMF, from a
histological and histomorphometric point of view.
Methods: An in vitro OA model was realized, culturing bovine cartilage explants with a high dose of interleukin
1β (IL1β, 50 ng/ml) at different experimental times (24 h, and 7 and 21 days). The effects of PEMFs (75 Hz, 1.5 mT)
were evaluated in cartilage explants treated with IL1β or not (control), in terms of cartilage structure, cellularity
and proteoglycans, glycosaminoglycans, collagen II and transforming growth factor β1 synthesis by using histology,
histomorphometry and immunohistochemistry.
Results: Making a comparison with control cartilage, IL1β-treated explants showed a decrease in cartilage matrix,
structure and cellularity parameters. PEMFs were able to counteract the progression of OA acting on both
cartilage cellularity and ECM in cartilage previously treated with IL1β. Normal distribution (Kolmogroc-Smirnov
test) and homoscedasticity (Levene test) of data were verified, then, the non-parametric Kruskal Wallis test
followed by Mann-Whiteny U test for pairwise comparisons were performed. The p-value was adjusted according
to the Dunn-Sidak correction.
Conclusions: These results, obtained by culturing and treating cartilage explants from two different joints,
confirmed that PEMF stimulation can be used as adjuvant therapy to preserve cartilage from detrimental effects
of high inflammatory cytokine levels during OA.
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Background
The presence of pro-inflammatory cytokines in the
joint microenvironment favors cartilage degeneration
and osteoarthritis (OA) progression with alterations of
proteoglycans (PGs) and collagen fibers, prevalently
collagen type II (Coll II) [1]. Among pro-inflammatory
cytokines, interleukin1β (IL1β) plays a pivotal role in
inducing degradation of extracellular matrix (ECM)
components and synthesis of other pro-inflammatory
cytokines, chemokines and proteolitic enzymes. Since
cartilage has a poor intrinsic reparative capability if not
treated, OA leads to progressive disability and require-
ment of joint arthroplasty [2].
Current therapeutic strategies to prevent OA include
the use of nonsteroidal anti-inflammatory drugs (NSAIDs)
[3], that act at articular and not cellular levels, intra-
articular injection of hyaluronic acid (HA) and physical
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exercises [4], that act only in the muscle of the joint.
These treatments relieve pain and inflammation and
improve functionality, but do not resolve the patho-
logical process once triggered, thus the outcomes are
inconclusive and remain as long as these therapies are
administered. For this reason, orthopedic research in-
vestigates chondroprotective treatments able to reduce
the local inflammatory microenvironment and to favor
damaged articular cartilage anabolic activity.
Pulsed electromagnetic field (PEMF) stimulation has
been already studied and proposed for the regeneration of
musculoskeletal tissues such as cartilage [5], bone [6, 7],
tendon [8] and ligament [9]. As far as cartilage tissue is
concerned, PEMFs positively affect chondrocyte prolifera-
tion and ECM component synthesis [10]. However, the
existing studies, performed with different PEMF physical
parameters and exposure times, gave contradictory results
[11–15], in terms of chondrocyte viability, DNA content,
glycosaminoglycans (GAGs), Coll II, PGs and aggrecan
gene expression and production. In a previous in vitro
study, on bovine cartilage explants, we conducted a dose–
response study to find the optimal dosage, in terms of
PEMF frequency and exposure intensity, able to stimulate
significantly PG synthesis [16]. Furthermore, the stimula-
tory effect of PEMFs on PG synthesis in presence of IL1β
and in combination with insulin-like growth factor 1
(IGF-I) was observed [17, 18]. PEMF and IGF-I showed an
additive effect on PG synthesis in human OA cartilage
explants cultured in the absence or presence of IL1β [19].
In in vivo studies, PEMF stimulation was able to limit the
progression of OA of increasing severity [20–22], to
reduce IL1β and tumor necrosis factor-α (TNF-α) concen-
trations and to increase transforming growth factor-β1
(TGFβ1) in the synovial fluid of sheep treated with autolo-
gous osteochondral grafts [23]. In clinical studies, PEMF
stimulation was successfully used to treat pain, knee swell-
ing and functionality, after total knee arthroplasty [24, 25]
and in early knee OA patients [26]. In other studies, bene-
ficial symptomatic effects [27, 28] or additional effects to
physical treatments [29] were not observed in OA
patients.
Even if PEMFs act on the joint microenvironment and
have anabolic and chondroprotective actions, the mecha-
nisms by which PEMFs exert their effects on biological
systems remain not completely understood. To our know-
ledge, no histological and histomorphometric evaluations
have assessed the effects of PEMF stimulation in an
inflammatory OA microenvironment obtained in vitro
with the addition of a high IL1β dose.
The present study aimed to analyze whether PEMF
stimulation (75 Hz, 1.5 mT), applied to bovine cartilage
explants, derived from two different joints of the same
animals, was able to counteract the catabolic effect of a
high dose of IL1β. In comparison to 2D monolayer
chondrocyte cultures, the cartilaginous 3D explants
cultured with IL1β are a well-accepted method to
measure and evaluate the effect and mechanism of
action of a therapy, by simultaneously evaluating chon-
drocytes and cartilage matrix and by closely mimicking
the clinical situation of OA joint, in which a high dose
of IL1β is found in the early stages of OA [30] and its
concentration can be further increased by surgical
intervention [2].
It was hypothesized that the PEMF stimulation alone,
without the addition of other biological stimuli, might
improve the production of the most important cartilage
ECM components (PGs, GAGs, COLL II) and anabolic
factor (TGF-β1) and preserve cartilage structure, thus
controlling OA development. To demonstrate this
hypothesis it was adopted an already set and validated
in vitro model of OA [18, 31], which used a high dose of
IL1β (50 ng/ml) to create an inflammatory OA micro-
environment. After 24 h, 7 and 21 days of culture,
PEMF effect, in combination or not with IL1β, was evalu-
ated through histological, histomorphometric and immu-
nohistochemical analyses. In this study it was observed
that PEMFs were able to counteract the progression of
OA acting on both cartilage cellularity and ECM in cartil-
age previously treated with IL1β.
Methods
Cartilage explant cultures and treatment conditions
Full-thickness explants of bovine articular cartilage were
aseptically dissected, by using a 4 mm dermal punch
(Stiefel Laboratories, Milan, Italy), from the metacarpo-
phalangeal(MC) and metatarsophalangeal (MT) joints of
14-18-month-old animals (Limousine breed), as previ-
ously described [16–18]. The abattoir gave permission
for the use of cartilage explants in this study and no eth-
ical approval, from a recognized ethics committee, was
required for this study. The cartilage was explanted
shortly after the bovine slaughter and cartilage discs
(three discs in each well) were cultured in 0.5 ml culture
medium in multiwells (Nunc, Denmark, 1.6 cm the
diameter of each well). Before PEMF exposure and IL1β
administration, all explants were allowed to equilibrate
in culture for 48 h in DMEM/F12 (Life Technologies,
Monza, Italy) supplemented with 10 % FBS and antibi-
otics (penicillin 100 units/ml, streptomycin 0.1 mg/ml)
(complete medium) and for an additional 48 h in
medium without serum, at 37 °C in an atmosphere of
5 % CO2. During the experiments, explants were cul-
tured in complete medium in the absence and presence
of IL1β (50 ng/ml) [18]. Half cultures were exposed to
PEMF throughout the entire culture period (24 h, 7 and
21 days). Medium was changed at the beginning of the
exposure (time 0) and every 3 days.
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For each experimental time, 4 experimental groups
were set up and each group was composed of 3 explant
discs from MC and 3 more from MT joints:
– Control group (CTR): cartilage explants;
– IL1β group: cartilage explants submitted to IL1β
administration;
– PEMF group: cartilage explants exposed to PEMFs;
– IL1β + PEMF group: cartilage explants submitted to
IL1β and exposed to PEMFs.
Characteristics of PEMFs and exposure conditions
The PEMF generator system was the same as that used
in previous studies [9, 16–18, 32, 33]. It consisted of a
pair of circular Helmoltz coils of copper wire placed
opposite to each other and in a signal generator (Igea
S.p.A., Carpi, Italy). The multiwell plates were placed be-
tween this pair of Helmoltz coils, so that the plane of
the coils was perpendicular to the multiwell plates, and
the direction of the induced electric field was perpen-
dicular to the direction of the magnetic field. The power
generator produced a pulsed signal with the following
parameters: the pulse duration was 1.3 ms and the fre-
quency was 75Hz, yielding a duty cycle of 1/10. The
intensity peak of the magnetic field was 1.5mT and the
induced electric field, as detected with a standard coil
probe (50 turns, 0.5 cm internal diameter of the coil
probe, 0.2 copper diameter), was 0.07 mV/cm.
The intensity of the magnetic field was detected
between two coils from one side to the other, by the Hall
probe of the Gaussmeter (LE, Gaussmeter DG500,
USA), with a reading sensitivity of 0.2 %. Inside this area,
where the multiwell plate was placed, the magnetic field
was uniform. Cartilage explants were exposed to con-
tinuous PEMF for 24 h, 7 or 21 days. PEMF unexposed
cultures were placed inside the same incubator at a dis-
tance where no difference from background magnetic
field was observed when the PEMF generator was turned
on. In each experiment, controls and treatments were
performed in triplicate wells.
Histology
At the end of the experimental times, cartilage explants,
cultured in the above mentioned conditions, were rou-
tinely processed for paraffin embedding procedures.
Briefly, samples were fixed for 24 h in 10 % neutral buff-
ered formalin solution in PBS, extensively rinsed in dis-
tilled water, dehydrated in graded alcohol solutions (70,
95 %, two times and 100 %, three times, one hour for
each step), cleared in xylene e finally paraffin embedded.
Sections (5 ± 1 μm) were cut along the longitudinal axis of
the samples by a semi-automated microtome (Microm
H340E, Germany) and stained with Toluidine Blue, for the
PG quantification and Safranin O-Fast green staining, for
the GAG quantification. Three non-consecutive sections
for each sample were evaluated, by 2 independent his-
tologists through a semi-quantitative score (modified
O’Driscoll score) [34]. The modified O’Driscoll score
(Table 1: minimum 0 = osteoarthritic cartilage - max-
imum 11 = normal intact cartilage) analyzed 4 cartilage
aspects: Safranin O staining, surface regularity, cellular-
ity and chondrocyte clustering.
Immunohistochemical stainings (TGFβ1 and Coll II)
Cartilage sections were dewaxed in decreasing graded
ethanol solutions until PBS rinsing for 20 min and then
immunostained for TGFβ1 and Coll II. Briefly, after fix-
ation, sections were extensively rinsed in PBS and
permeabilized by incubation in 0.3 % hydrogen peroxide
in PBS solution for 15 min. For Coll II immunostaining,
sections were pre-treated for antigen unmasking with
0.2 % Pronase (P-8811, Sigma, Mo, USA) solution in
PBS for 30 min at 37 °C. Then, 10 % normal serum was
added for 1 h at room temperature to block nonspecific
antibody binding and the primary antibodies (rabbit
polyclonal antibody anti TGFβ1, sc-146 and mouse
monoclonal antibody anti collagen II, sc-52658, 1:50
dilutions, Santa Cruz Biotechnology, CA, USA) were
applied and incubated overnight at 4 °C. After rinsing in
PBS, slides were incubated with appropriate biotinylated
secondary antibody and with horseradish peroxidase-
streptavidin complex for 1 h each (ABC Staining System,
Biotechnology, CA, USA). Sample reaction was developed
with 3,3-diaminobenzidine substrate and permanently
mounted. Negative controls, by omitting the primary
antibody, were included to check proper specificity and
performance of the applied reagents.
Table 1 Modified O’Driscoll score
Parameter Feature Grade




Surface regularity Smooth and intact 3
Superficial horizontal lamination 2
Fissures 25–100 % of the thickness 1
Severe disruption, including fibrillation 0




Chondrocyte clustering No clusters 2
<25 % of the cells 1
25–100 % of the cells 0
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Histomorphometric measurements
Slices stained with Toluidine Blue or Safranin O-Fast
Green and immunostained for TGFβ1 or Coll II were
observed by a light microscope (BX51, Olympus Italia
Srl, Segrate-Milano, Italy) and three Regions of Interest
(ROI) for each slide were grabbed at a 40× magnifica-
tion. Image analysis by Leica Q-Win Software (Leica
Microsystem, Wetzlar, Germany) was performed and the
threshold applied was One-dimensional (LUTs: Lookup
Table Transforms) based on selected ranges of RGB
channels to measure the following parameters expressed
as percentage:
– GAGs, as the ratio between the Safranin O stained
areas and the total ROI areas;
– PGs, as the ratio between the Toluidine Blue stained
areas and the total ROI areas;
– TGFβ1, as the ratio between the immunopositive
stained areas and the total ROI areas;
– Coll II, as the ratio between the immunopositive
stained areas and the total ROI areas.
Statistical analysis
Statistical analysis was performed using the IBM SPSS
Statistics v.21.0 software (IBM Corp, USA). Firstly, nor-
mal distribution (Kolmogroc-Smirnov test) and homo-
scedasticity (Levene test) of data were verified, then, the
non-parametric Kruskal Wallis test followed by Mann-
Whiteny U test for pairwise comparisons were per-
formed. The P-value was adjusted according to the
Dunn-Sidak correction [adj p = 1 - (1 – p)k, where k is
the number of pairwise comparisons]. Since the prelim-
inary Kruskal-Wallis test by distinguish MC and MP
joints did not show significant differences between the
two harvesting sites within each type of treatment, data
were analyzed when merged.
Results
The in vitro cartilage OA model after IL1β administration
In the CTR Group the production of PGs, GAGs and
COLL II significantly decreased at 7 days in comparison
with cultures at 24 h by −47 % (p = 0.022), −58 % (p =
0.008) and −27 % (p = 0.038), respectively (Figs. 1, 2, 3).
As expected, the treatment with IL1β significantly
decreased the PGs, GAGs, Coll II and TGFβ1 produc-
tion in cartilage explants as compared to CTR at each
experimental time, except for TGFβ1 at 21 days
(Figs. 1, 2, 3, 4). Specifically, PGs decreased by 96–
99 % (at 24 h p = 0.0005, at 7 days p = 0.0005 and at
21 days p = 0.0005), GAGs by 88 % at 24 h (p = 0.0005)
and about 73 % at 7 (p = 0.008) and 21 (p = 0.03) days and
Coll II by 92–96 % (at 24 h p = 0.0005, at 7 days p =
0.0005 and at 21 days p = 0.04) (Figs. 1, 2, 3). The produc-
tion of TGFβ1 significantly decreased at 24 h (p = 0.0005,
47 %) and 7 days (p = 0.017, 68 %) (Fig. 4). Figure 5 shows
the immunohistochemical and histological images of
explants stained for Coll II, TGFβ1 and Safranin O at 24 h
and 21 days.
Because of the IL1β effect, the O’Driscoll score pro-
gressively worsened by 50–60 %, during the experimen-
tal times, in comparison to CTR (at 24 h p = 0.0005, at
7 days p = 0.0005 and at 21 days p = 0.04) (Fig. 6). By
analyzing each score parameter (Table 2), it was noted
Fig. 1 Boxplots of histomorphometric measurements of PGs expressed
as percentage in bovine cartilage explants. Black line =median; extreme
values =minimum-maximum. Control (CTR), exposed to PEMF (PEMF),
treated with IL1β (IL1β) or treated with IL1β and stimulated with PEMF
(IL1β+ PEMF) explants. 24 h, 7 and 21 days (n= 6). Mann-Whitney U test:
- Within each experimental time: IL1β versus CTR (**, p< 0.005); IL1β+
PEMF versus IL1β (§, p< 0.05); - Within each group: 7 days versus 24 h
(a, p< 0.05)
Fig. 2 Boxplots of histomorphometric measurements of GAGs
expressed as percentage in bovine cartilage explants. Black
line = median; extreme values = minimum-maximum. Control (CTR),
exposed to PEMF (PEMF), treated with IL1β (IL1β) or treated with
IL1β and stimulated with PEMF (IL1β + PEMF) explants. 24 h, 7 and
21 days (n = 6). Mann-Whitney U test: - Within each experimental
time: IL1β versus CTR (*, p < 0.05; **, p < 0.005); PEMF versus CTR
(°, p < 0.05; °°, p < 0.005); IL1β + PEMF versus IL1β (§, p < 0.05; §§, p
< 0.005); - Within each group: 7 days versus 24 h (a, p < 0.05)
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that, the cellularity (p = 0.025) and chondrocyte cluster-
ing (p = 0.025) decreased significantly by 50 % in the
CTR group from 7 to 21 days and from 24 h to 7 days,
respectively. At 24 h, the reduction induced by IL1β on
each O’Driscoll score parameter in comparison with
CTR was 50 % for Safranin-O staining (p = 0.0005), sur-
face regularity (p = 0.002) and cellularity (p = 0.0005) and
75 % for chondrocyte clustering (p = 0.0005), whereas at
7 and 21 days it was 50 % for surface regularity (at 7 days
p = 0.0005 and at 21 days p = 0.0005), 50–100 % for
cellularity (at 7 days p = 0.001 and at 21 days p = 0.001)
and 100 % for chondrocyte clustering (at 7 days p =
0.001 and at 21 days p = 0.02).
Effects of PEMF stimulation
As also observed by histology in Fig. 5, in bovine cartilage
explants stimulated by PEMF, no significant increases in
PGs were found in comparison with CTR explants at each
experimental time (Fig. 1). Conversely, PEMF stimulated
GAG production at 7 (p = 0.0005, 170 %) and 21 (p =
0.005, 151 %) days, as well as Coll II (p = 0.005, 59 %) and
TGFβ1 (p = 0.005, 58 %) at 7 days (Figs. 2, 3, 4). By analyz-
ing data over time, Coll II in the PEMF group diminished
from 7 to 21 days (p = 0.004, 38 %).
When bovine cartilage explants were cultured with IL1β
and were stimulated with PEMFs, very high increases in
PG production compared to the IL1β group were ob-
served at 24 h (p = 0.01, 439 %) and 21 days (p = 0.04,
235 %) (Fig. 1). The IL1β + PEMF group also showed in-
creases in GAG production in comparison to the IL1β
group at 24 h (p = 0.0005, 684 %), 7 (p = 0.02, 250 %) and
21 days (p = 0.01, 307 %) (Fig. 2). Coll II increased mas-
sively in the IL1β + PEMF group at 24 h (p = 0.002,
1890 %), 7 (p = 0.02, 835 %) and 21 days (p = 0.007,
734 %) in comparison to IL1β (Fig. 3). GAG and Coll II
synthesis decreased by 57 % (p = 0.02) and 35 % (p =
0.02), respectively, from 24 h to 7 days in the IL1β +
PEMF group. Regarding TGFβ1 production, it in-
creased progressively at all experimental times (at 24 h
p = 0.005, 71 %, at 7 days p = 0.02, 184 % and at 21 days
p = 0.007, 204 %) in comparison to the IL1β group
(Fig. 4).
The O’Driscoll score results of the PEMF-treated group
did not differ from those of the CTR group at each experi-
mental time (Fig. 6). Taking into account each O’Driscoll
score parameter (Table 2), PEMF stimulation improved
chondrocyte clustering at 7 days (p = 0.0005, 100 %) and
Safranin-O staining at 7 (p = 0.0005, 100 %) and 21 days
(p = 0.03, 200 %) compared to that of the CTR group.
The effect of PEMF stimulation, applied to IL1β-treated
cartilage explants (IL1β + PEMF group), improved the
O’Driscoll score in comparison to the IL1β group, at both
24 h (p = 0.02, 75 %) and 21 days (p = 0.03, 150 %) (Fig. 6).
A decrease in O’Driscoll score was highlighted between
24 h and 7 days in the IL1β + PEMF group (p = 0.007,
43 %). The IL1β + PEMF group improved by about 100 %
for Safranin-O staining (p = 0.02) and cellularity (p =
0.003) at 24 h, for chondrocyte clustering (p = 0.008) and
Safranin-O staining (p = 0.008) at 7 days, and for surface
regularity (p = 0.003), Safranin-O staining (p = 0.001),
chondrocyte clustering (p = 0.005) and cellularity (p =
0.001) at 21 days compared to those of the IL1β group
(Table 2). In addition, surface regularity of the IL1β +
Fig. 3 Boxplots of histomorphometric measurements of Coll II
expressed as percentage in bovine cartilage explants. Black
line = median; extreme values = minimum-maximum. Control (CTR),
exposed to PEMF (PEMF), treated with IL1β (IL1β) or treated with IL1β
and stimulated with PEMF (IL1β + PEMF) explants. 24 h, 7 and 21 days
(n = 6). Mann-Whitney U test: - Within each experimental time: IL1β
versus CTR (*, p < 0.05; **, p < 0.005); PEMF versus CTR (°, p < 0.05); IL1β
+ PEMF versus IL1β (§, p < 0.05; §§, p < 0.005); - Within each group:
7 days versus 24 h (a, p < 0.05); 21 days versus 7 days (b, p < 0.005)
Fig. 4 Boxplots of histomorphometric measurements of TGF-β1
expressed as percentage in bovine cartilage explants. Black
line = median; extreme values = minimum-maximum. Control (CTR),
exposed to PEMF (PEMF), treated with IL1β (IL1β) or treated with
IL1β and stimulated with PEMF (IL1β + PEMF) explants. 24 h, 7 and
21 days (n = 6). Mann-Whitney U test: - Within each experimental
time: IL1β versus CTR (*, p < 0.05; **, p < 0.005); PEMF versus CTR
(°, p < 0.05); IL1β + PEMF versus IL1β (§, p < 0.05)
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PEMF group decreased by 50 % (p = 0.003) from 24 h to
7 days (Table 2).
Discussion
The present study aimed to evaluate the effects and mech-
anisms of action of PEMF stimulation (75 Hz, 1.5 mT) in
preserving cartilage from OA structural deterioration. The
in vitro effects were investigated on bovine cartilage ex-
plants harvested from two different joints. To simulate the
OA microenvironment, a high IL1β concentration (50 ng/
ml) was administered in explant cultures, as set in an our
previous in vitro study [30], for a longer period of 21 days
and the changes in the structure and cellularity of CTR
and IL1β-treated cartilage explants, either exposed or not
to PEMFs, were analyzed. The concentration of IL-1β
found in the synovial fluid of patients affected by OA is
between 0.068 and 0.33 pg/ml [35]. However, most of the
in vitro literature studies, that aimed to re-create an in-
flammatory microenvironment, added 10 ng/ml of IL-1β
in the medium of cartilage explants [36–38], while there
are other authors that employed 50 or 100 ng/ml [39–41].
The so high concentration of IL-1β used in the present
study was chosen to employed an intermediate cytokine
dosage and to evaluate if PEMF stimulation is able to
restore cartilage ECM biological and morphological prop-
erties also with a huge concentration of IL-1β than the
most employed one (10 ng/ml). The current data con-
firmed the hypotheses of the study. The addition of a high
dose of IL1β to the culture medium induced a significant
reduction, not only in structural parameters, but also
ECM components and TGFβ1 synthesis, a decline
observed at all experimental times until 21 days. These
results are in agreement with those of previous in vitro
studies, that observed GAGs, PGs and Coll II loss with
the addition of IL1β in the culture medium of human, bo-
vine and horse cartilage explants [30, 42, 43]. Although
the joint inflammatory microenvironment of OA consists
of different inflammatory mediators, such as matrix metal-
loproteinases (MMPs), the disintegrin and metalloprotein-
ases with thrombospondin motifs (ADAMTs) and other
pro-inflammatory cytokines, TNF-α and Interleukin-6 (IL-
6), data suggested that IL1β might have the strongest
effect. Indeed, with the addition of IL1β in the culture
medium, the most important components of cartilage
ECM and TGFβ1 synthesis were reduced and other cartil-
age structural parameters (matrix and cellularity) were
Fig. 5 Immunohistochemical and histological images of bovine cartilage explants. Control (CTR), exposed to PEMF (PEMF), treated with IL1β
(IL1β) or treated with IL1β and stimulated with PEMF (IL1β + PEMF) explants. 24 h and 21 days. Magnification at 20x. Bar = 70 μm. Negative
control column contains 4 images of the negative control of the relative markers (COLL II and TGFβ1)
Fig. 6 Boxplots of total O’Driscoll modified score in bovine cartilage
explants. Black line =median; extreme values = minimum-maximum.
Control (CTR), exposed to PEMF (PEMF), treated with IL1β (IL1β) or
treated with IL1β and stimulated with PEMF (IL1β + PEMF) explants.
24 h, 7 and 21 days (n = 6). Mann-Whitney U test: - Within each
experimental time: IL1β versus CTR (*, p < 0.05; **, p < 0.005); IL1β +
PEMF versus IL1β (§, p < 0.05); - Within each group: 7 days versus
24 h (a, p < 0.05)
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compromised. Coll II, PGs and GAGs are the most abun-
dant components of cartilage ECM, which are responsible
for the ECM organization and give shear and tensile prop-
erties and the ability to resist compressive loads to
cartilage.
Secondly, the stimulation with PEMFs, applied to
healthy explants, did not modify PG content or the
structural parameters at any of the experimental times,
and moreover, increases in GAGs and Coll II were ob-
served after 24 h of culture. Instead, PEMFs improved
all the analyzed ECM proteins and the structural param-
eters in IL1β-treated explants, also at 21 days of culture.
Similar results were published by Brighton et al., in 2006
and 2008 using capacitively coupled electric fields
(CCEF). They observed an increase in Coll II and PG
production in human and bovine cartilage explants,
treated or not with IL1β, after stimulation [44, 45].
Finally, in this study it was also observed that IL1β and
PEMFs have an opposite effect on TGFβ1, the anabolic
growth factor that induces matrix production, mesen-
chymal stem cell chondrogenic differentiation and chon-
drocyte proliferation [46].
This study allowed a more complete view of the role
of PEMFs that has been already investigated in previous
our in vitro studies [18, 31]. The strengths of the study
were: 1) the histological and histomorphometric evalua-
tions on in vitro cartilage explants, stimulated with
PEMF parameters already used in patients suffering
from knee pain due to cartilage degeneration [47]; 2) the
long-term culture of cartilaginous explants (21 days) and
3) the comparative analysis in two different joints. A
limitation of the study was the absence, in the culture
explants model, of the subchondral bone, that is recog-
nized to play a role in OA development. It is noteworthy
that the score employed in this study is a modification
of the score proposed by O’Driscoll SW, et al., in 1988
[34]: only the parameters that regard the matrix, the
structure and the chondrocyte hypocellularity and clus-
tering could be evaluated.
In comparison to 2D monolayer chondrocyte cultures
and in vivo situation, the 3D cartilage explants, adopted in
this study, are a more homogenous model to evaluate car-
tilage metabolism. Chondrocytes are maintained in their
physiological microenvironment, the de-differentiation
phenomenon is prevented and the inter-individual vari-
ables are reduced [48]. In addition, the use of cartilage
explants is a more suitable in vitro method than chondro-
cytes embedded in alginate cultures to study PEMF and
IL1β effects, because the chondrocytes are embedded in
their native ECM. In fact the changes in ECM compos-
ition may play an important role in maintaining osteo-
arthritis damage and the alterations in hyaluronate
degradation can be an alternative mechanism for the
regulation of proteoglycan release from cartilage fol-
lowing IL1β stimulation [49]. 3D explants are reliable
even at long experimental times because the effects of
IL1β treatment and PEMF stimulation were evident
also at 21 days of culture. Many in vitro culture studies
evaluated bovine cartilage because of the advantageous
easy availability and similar thickness to human cartil-
age [50]. Moreover, the metabolic activity and struc-
tural composition of bovine cartilage is reported to be
quite similar to those of humans [50].
Conclusions
This study shows that the addition of IL1β to the culture
medium has a detrimental effect on cartilage explants by
reducing PG, GAG, Coll II and TGFβ1 quantification and
Table 2 Median values (minimum and maximum values) of O’Driscoll modified score parameters in cartilage explants
Experimental time O’driscoll score parameters CTR IL1β PEMF IL1β + PEMF
24 h Safranin-O staining 2 (2–3) 1 (1–2)** 3 (2–3) 2 (2–2)§
Surface regularity 2 (2–3) 1 (1–2)** 3 (3–3) 2 (2–2)
Chondrocyte clustering 2 (1–2) 0.5 (0–1)** 2 (2–2) 1 (1–2)
Cellularity 2 (2–3) 1 (1–1)** 3 (2–3) 2 (1–2)§§
7 days Safranin-O staining 1 (1–2) 0 (0–1) 3 (2–3)°° 1 (1–2)§
Surface regularity 2 (1–3) 1 (0–1)** 3 (2–3) 1 (1–2)
Chondrocyte clustering 1 (1–1) 0 (0–1)**,a 2 (1–2)°° 1 (1–2)§
Cellularity 2 (1–2) 1 (0–1)** 2 (2–3) 1 (1–2)
21 days Safranin-O staining 1 (1–2) 0 (0–1) 2 (2–2)° 1 (1–1)§§
Surface regularity 2 (1–2) 1 (1–1)** 2 (2–2) 2 (1–2)§§, b
Chondrocyte clustering 1 (1–1) 0 (0–0)* 1 (1–1)b 1 (1–2)§
Cellularity 1 (1–1) 0 (0–1)**,a 1.5 (1–2) 1 (1–1)§§
Control (CTR), exposed to PEMF (PEMF), treated with IL1β (IL1β) or treated with IL1β and stimulated with PEMF (IL1β + PEMF) explants. 24 h, 7 and 21 days (n = 6)
Mann-Whitney U test: - Within each experimental time: IL1β versus CTR (*, p < 0.05; **, p < 0.005); PEMF versus CTR (°, p < 0.05; °°, p < 0.005); IL1β + PEMF versus IL1β
(§, p < 0.05; §§, p < 0.005); Within each group: 7 days versus 24 h (a, p < 0.05); 21 days versus 7 days (a, p < 0.05; b, p < 0.005)
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O’Driscoll modified score parameters. PEMF stimulation
is able to counteract these catabolic effects both on ECM
and chondrocyte features. It was also found that PEMFs
have a greater effect on cartilage explants compromised
by IL1β in comparison to normal tissues. These results
confirm the role of PEMFs in chondroprotection and, as
shown by the long-term results, they suggest their ability
to limit OA progression.
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